{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:24:32Z","timestamp":1789928672529,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"FEETEG","award":["01-04"],"award-info":[{"award-number":["01-04"]}]},{"name":"FEETEG","award":["EC07\/90737"],"award-info":[{"award-number":["EC07\/90737"]}]},{"name":"FEETEG","award":["07\/90938"],"award-info":[{"award-number":["07\/90938"]}]},{"name":"FEETEG","award":["PS09\/02556"],"award-info":[{"award-number":["PS09\/02556"]}]},{"name":"FEETEG","award":["PS12\/01219"],"award-info":[{"award-number":["PS12\/01219"]}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.017","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T21:47:52Z","timestamp":1477345672000},"page":"173-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project"],"prefix":"10.1016","volume":"68","author":[{"given":"Pilar","family":"Giraldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Andrade-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Irun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koldo","family":"Atutxa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Acedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abelardo","family":"Barez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Blanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Diaz-Morant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Angeles","family":"Fern\u00e1ndez-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gil-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0999-9442","authenticated-orcid":false,"given":"Vicente","family":"Giner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Latre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Loyola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-6534","authenticated-orcid":false,"given":"Elisa","family":"Lu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Hern\u00e1ndez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Medrano-Engay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-1101","authenticated-orcid":false,"given":"Javier","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Salamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Villal\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pocovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.017_bb0005","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"1995"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","article-title":"Gaucher's disease: clinical features and natural history","volume":"10","author":"Cox","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0015","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90042-6","article-title":"Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment","volume":"97","author":"Zimran","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007990802576518","article-title":"Goal-oriented therapy with miglustat in Gaucher disease","volume":"25","author":"Pastores","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","article-title":"Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase","volume":"96","author":"Rosenthal","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/bcmd.1996.0016","article-title":"Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement","volume":"22","author":"Elstein","year":"1996","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/bcmd.1995.0012","article-title":"The clinical course of treated and untreated Gaucher disease. A study of 45 patients","volume":"21","author":"Beutler","year":"1995","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0055","series-title":"Prescribing Information","author":"Actelion","year":"2010"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0060","author":"Actelion, Zavesca\u00ae (miglustat capsules)"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0065","series-title":"Summary of Product Characteristics","author":"Actelion, Miglustat (Zavesca)","year":"2014"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0070","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0075","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project","volume":"94","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0080","first-page":"703","article-title":"Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease","volume":"91","author":"Giraldo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0085","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejrad.2006.11.024","article-title":"S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease","volume":"62","author":"Roca","year":"2007","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0110","unstructured":"http:\/\/feeteg.org\/G_conocer.php. Accessed 30 September 2016 (2016)"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/pds.3760","article-title":"Results from a 9-year Intensive Safety Surveillance Scheme (IS(3)) in miglustat (Zavesca((R)))-treated patients","volume":"24","author":"Brand","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13256-015-0617-5","article-title":"Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series","volume":"9","author":"Serratrice","year":"2015","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0125","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0135","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","article-title":"Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease","volume":"282","author":"Brumshtein","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0145","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/00498250601094543","article-title":"The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat","volume":"37","author":"Treiber","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0155","first-page":"1346","article-title":"Comparison of bone mineral density with dual energy X-ray absorptiometry, quantitative ultrasound and single energy X-ray absorptiometry","volume":"26","author":"El-Desouki","year":"2005","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0160","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0165","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/jnnp.2006.111518","article-title":"Neurological evaluation of patients with Gaucher disease diagnosed as type 1","volume":"79","author":"Capablo","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcmd.2016.10.017_bb0175","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2016.10.017_bb0180","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin. Ther."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616301334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616301334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:27Z","timestamp":1761050067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616301334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":36,"alternative-id":["S1079979616301334"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.017","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}